Drug Profile
Research programme: anti PD-1 antibodies - Cellectis/MabQuest
Latest Information Update: 28 Apr 2020
Price :
$50
*
At a glance
- Originator Cellectis; MabQuest
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants; Programmed cell death-1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2020 No recent reports of development identified for research development in Cancer in France (Parenteral)
- 16 Mar 2016 Early research in Cancer in France (Parenteral)
- 16 Mar 2016 Cellectis and MabQuest enter into research collaboration and license agreement to develop monoclonal antibodies targeting PD-1